Fig. 2: P2G3 neutralizes spike-coated pseudoviruses and live virus VOCs.
a, Neutralization of lentiviral particles pseudotyped with SARS-CoV-2-spike-expressing VOCs in a 293T-ACE2 infection assay. All spike proteins contained the D614G substitution that became dominant early in the pandemic. Replicates in the concentration response curves were n = 5, 5, 6, 8 and 6 for the 2019-nCoV, Alpha, Beta, Delta and Omicron variants, respectively. b, Neutralization of lentiviral particles pseudotyped with the Omicron variant spike. Antibody cocktails represent a 1:1 mix of each mAb to give the indicated total mAb concentration. Replicates for mAbs in order of appearance in the legend are n = 9, 9, 9, 7, 7, 7, 7, 7 and 6. c–e, Neutralization activity of P2G3 performed in a live SARS-CoV-2 infectious virus cytopathic effect assay (CPE). The indicated SARS-CoV-2 variants were used to infect Vero E6 cells in vitro in the absence and presence of concentration response of the indicated mAb. Viral inhibition curves are shown for the Delta (c, n = 4 replicates), Omicron BA.1 (d, n = 4 replicates) and Omicron BA.2 (e, n = 6 replicates for P2G3 and P5C3, n = 4 for P2G3+P5C3 and n = 2 for the remaining mAbs) variants for individual and mAb combinations. f, Heat map showing IC50 and IC80 neutralization potencies for the indicated mAbs in the live virus CPE assays calculated from c–e. For a–e, mean ± s.e.m. are shown.
